3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Wilms Tumor
6
Testicular Neoplasms
5
Neuroblastoma
5
Sarcoma
4
Rhabdomyosarcoma
4
Medulloblastoma
4
Kidney Neoplasms
4
Central Nervous System Neoplasms
4
Carcinoma, Renal Cell
4
Sarcoma, Ewing
3
Rhabdoid Tumor
3
Retinoblastoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Lymphoma
3
Hepatoblastoma
3
Brain Neoplasms
3
Astrocytoma
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Optic Nerve Glioma
2
Neoplasms, Plasma Cell
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Liver Neoplasms
2
Interventions
Melphalan
1
Lenograstim
1
1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castrate Resistant Prostate Cancer
×
Melphalan
×
Genitourinary
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled